Award recordCONTRACT

AMNEAL PHARMACEUTICALS OF NEW YORK, LLC

PIID 36C26026F0059· VHA· 260-NETWORK CONTRACT OFFICE 20 (36C260)· 6505 · DRUGS AND BIOLOGICALS· FY2026· $319,399 net obligations· UEI LVEBAQTPN615· NY

Description

PHARMACEUTICAL - XYREM (SODIUM OXYBATE) - 2026 PRICE INCREASE & DOSAGE USED.

Base award description: PHARMACEUTICAL - XYREM (SODIUM OXYBATE)

First action · last action
2025-10-07 · 2026-03-06
Transactions
3
First transaction's obligation
$311,472
Base + all options value (sum of deltas)
$319,399
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
3
SDVOSB flag on record
No
Parent IDV
36F79722D0161
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 3 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$319,399$0Base award · 2025-10-07 · this action $311,472 · running total $311,472Modification P00001 · 2025-10-21 · this action $0 · running total $311,472Modification P00002 · 2026-03-06 · this action $7,927 · running total $319,399
  • Base2025-10-07+$311,472= $311,472
  • Mod P000012025-10-21+$0= $311,472
  • Mod P000022026-03-06+$7,927= $319,399
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2025-10-07+$311,472$311,472PHARMACEUTICAL - XYREM (SODIUM OXYBATE)
Mod P00001· OTHER ADMINISTRATIVE ACTION2025-10-21+$0$311,472PHARMACEUTICAL - XYREM (SODIUM OXYBATE)
Mod P00002· FUNDING ONLY ACTION2026-03-06+$7,927$319,399PHARMACEUTICAL - XYREM (SODIUM OXYBATE) - 2026 PRICE INCREASE & DOSAGE USED.

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI LVEBAQTPN615)

AwardOffice · PSC / listingNet obligationsFY
36E79726A0013NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36C26025F0044260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$173,089FY2025
36C26024F0050260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$185,400FY2024
36E79724A0001NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2024
36F79722D0161NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS$0FY2022
36E79719N0017NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$100,295FY2019

Other recipients under 6505 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C26026F0379COSETTE PHARMACEUTICALS, INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$3,466FY2026
36C26026P0671MCKESSON PLASMA AND BIOLOGICS LLC260-NETWORK CONTRACT OFFICE 20 (36C260)$18,262FY2026
36C26026F0349AGIOS PHARMACEUTICALS, INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$73,080FY2026
36C26026F0306BRACCO DIAGNOSTICS INC.260-NETWORK CONTRACT OFFICE 20 (36C260)$337,422FY2026
36C26026F0298PROGENICS PHARMACEUTICALS INC260-NETWORK CONTRACT OFFICE 20 (36C260)$469,134FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26026F0059_3600_36F79722D0161_3600 · retrieved 2026-09-26.